Pressure BioSciences has continued to add research and development personnel to its staff to expand the number, as well as the scope, of R&D projects underway. The Company anticipates that its increased investments in R&D will complement its commercialization efforts by encouraging the continued publication of application notes in areas currently using PCT technology and creating new inventions that rely on its PCT technology.
The Company recently announced that a study focused on the discovery and identification of potential biomarkers of colon cancer was presented at the Annual Scientific Meeting of the American College of Gastroenterology (ACG). The study specifically used PCT technology for the extraction of proteins from colon cancer tissue. The results generated show that a tumor signature protein extracted from colon tumor tissue might be a biomarker for colon cancer. Patients could be treated earlier in the disease if reliable biomarkers can be identified for colon cancer.
Nearly a month later scientists at the New York University School of Medicine announced that the use of Pressure BioSciences’ ProteoSolveLRS method combined with PCT was actively involved in identifying potential biomarkers in breast and colon cancer tissue. The reported results were presented during the recent LC-MS Course and Symposium, Robinson College, Cambridge, England by Dr. Paul Pevsner of the NYU School of Medicine, Department of Pharmacology.
Furthermore, the Company was named the recipient of the prestigious 2007 North American Frost and Sullivan Award for Technology Innovation. The award was given to Pressure BioSciences because its technology can extract proteins from lipid-rich tissues without the use of detergents. This cutting-edge method results in higher protein recovery, enhanced reproducibility, and significant advantages in speed and handling.
As stated by Dutton Associates in a recent research report, which included a $10.00 Price target, “Internal and external research into additional uses of Pressure Cycling Technology further validates Pressure BioSciences’ approach to sample preparation and adds to the attractiveness of the technology and the Company.”
Let us hear your thoughts: Pressure BioSciences, Inc. Message Board
